AI assistant
DEXCOM INC — Director's Dealing 2017
Mar 14, 2017
30198_dirs_2017-03-14_a73b1718-5e12-4ba5-a35b-29c3a6b3ed26.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2017-03-10
Reporting Person: Balo Andrew K (EVP, Clinical and Regulatory)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-03-10 | Common Stock | S | 3200 | $77.71 | Disposed | 129463 | Direct |
| 2017-03-10 | Common Stock | D | 3528 | $77.5506 | Disposed | 125935 | Direct |
| 2017-03-10 | Common Stock | D | 6694 | $77.5506 | Disposed | 119241 | Direct |
| 2017-03-10 | Common Stock | D | 3208 | $77.5506 | Disposed | 116033 | Direct |
Footnotes
F1: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2: Included in this number are 69,927 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018.
F3: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.